SNORA21: A Potential Drug Target and Biomarker for Small Nucleolar RNA H/ACA Box 21

Target Name: SNORA21

NCBI ID: G619505

SNORA21

Other Name(s): Small nucleolar RNA, H/ACA box 21 | ACA21 | small nucleolar RNA, H/ACA box 21

SNORA21: A Potential Drug Target and Biomarker for Small Nucleolar RNA H/ACA Box 21

Small nucleolar RNA (snRNA) is a non-coding RNA molecule that plays a crucial role in the regulation of gene expression in eukaryotic cells. One of the key functional groups of snRNA is the H/ACA box 21, which is located within the snRNA molecule and is involved in the formation of double-stranded RNA structures. H/ACA box 21 is also known as the switch A site, and it has been shown to play a critical role in the regulation of snRNA stability and function.

Recent studies have identified SNORA21 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will provide an overview of SNORA21, its functions in the regulation of snRNA biology, and its potential as a drug target.

Functional Characterization of SNORA21

SNORA21 is a 24.8-kcalium phosphate (CaP)-containing RNA molecule that has a length of 192 nucleotides and a 5'-end that is protected by a poly(A) tail. It has a single exon and is expressed in all eukaryotic cells. SNORA21 is highly stable and has been shown to have a stable expression level in various cell types, including HeLa, HL10, and PC12 cells.

SNORA21 has been shown to play a critical role in the regulation of snRNA stability and function. It has been shown to form double-stranded RNA structures with other snRNAs, including snRNA-protein interactions, and has been shown to interact with various cellular factors, including RNA-protein interactions, histone modifications, and microRNA targets.

In addition, SNORA21 has also been shown to play a critical role in the regulation of gene expression. It has been shown to interact with various protein coding genes, including coding for the heat shock protein (HSP70), the kinesin-associated protein (KAP), and the tumor suppressor gene TP53. Additionally, SNORA21 has been shown to interact with non-coding RNA genes, including the microRNA (miRNA) target miR-202, and has been shown to regulate the expression of miR-202.

Potential Drug Target and Biomarker

SNORA21 has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Here, we will focus on the potential drug targeting aspect of SNORA21.

SNORA21 has been shown to be overexpressed in various cancer types, including breast cancer, lung cancer, and colon cancer. Additionally, SNORA21 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and angiogenesis, which are critical processes in cancer development. Therefore, SNORA21 could be a useful drug target for cancer treatment.

SNORA21 has also been shown to be involved in the regulation of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. SNORA21 has been shown to interact with the protein huntingtin (HNT), which is a neurodegenerative protein that is involved in the development of neurodegenerative diseases. Therefore, SNORA21 could be a potential drug target for neurodegenerative diseases.

SNORA21 has also been shown to be involved in the regulation of autoimmune disorders, including rheumatoid arthritis (RA) and multiple sclerosis (MS). SNORA21 has been shown to interact with the immune protein interleukin-1 (IL-1), which is involved in the regulation of immune responses and has been implicated in the development of autoimmune disorders. Therefore, SNORA21 could be a potential drug target

Protein Name: Small Nucleolar RNA, H/ACA Box 21

The "SNORA21 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNORA21 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets